322 related articles for article (PubMed ID: 26430073)
21. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
22. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
24. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
Rawstron AC; de Tute RM; Haughton J; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
[TBL] [Abstract][Full Text] [Related]
25. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.
Wang N; Tesfaluul N; Li J; Gao X; Liu S; Yue B
Ann Hematol; 2019 Dec; 98(12):2769-2780. PubMed ID: 31748925
[TBL] [Abstract][Full Text] [Related]
26. Molecular and clinical follow-up after treatment of multiple myeloma.
Rasmussen T; Knudsen LM; Huynh TK; Johnsen HE
Acta Haematol; 2004; 112(1-2):105-10. PubMed ID: 15179010
[TBL] [Abstract][Full Text] [Related]
27. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
29. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains.
Pratt G; Mead GP; Godfrey KR; Hu Y; Evans ND; Chappell MJ; Lovell R; Bradwell AR
Leuk Lymphoma; 2006 Jan; 47(1):21-8. PubMed ID: 16321823
[TBL] [Abstract][Full Text] [Related]
30. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
31. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
Guan L; Su W; Zhong J; Qiu L
Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
[TBL] [Abstract][Full Text] [Related]
32. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
[TBL] [Abstract][Full Text] [Related]
33. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
[TBL] [Abstract][Full Text] [Related]
34. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease in multiple myeloma: why, when, where.
Yee AJ; Raje N
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):37-45. PubMed ID: 34889430
[TBL] [Abstract][Full Text] [Related]
36. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
[TBL] [Abstract][Full Text] [Related]
37. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
Rustad EH; Boyle EM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
[TBL] [Abstract][Full Text] [Related]
38. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Mohan M; Szabo A; Yarlagadda N; Gundarlapalli S; Thanendrarajan S; Kendrick S; Schinke C; Alapat D; Sawyer J; Tian E; Tricot G; van Rhee F; Zangari M
Am J Hematol; 2021 Sep; 96(9):E341-E344. PubMed ID: 34050985
[No Abstract] [Full Text] [Related]
39. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.
Came N; Nguyen V; Westerman D; Harrison S
Br J Haematol; 2016 Jun; 173(6):947-9. PubMed ID: 26456706
[No Abstract] [Full Text] [Related]
40. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma.
Abeykoon JP; Murray DL; Murray I; Jevremovic D; Otteson GE; Dispenzieri A; Arendt BK; Dasari S; Gertz M; Gonsalves WI; Kourelis TV; Muchtar E; Dingli D; Warsame R; Go RS; Lacy MQ; Leung N; Buadi F; Lin Y; Kyle RA; Rajkumar V; Kumar S; Kapoor P
Br J Haematol; 2021 Apr; 193(2):380-385. PubMed ID: 33216966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
